Chris Brinsmead - Chairman
Chris Brinsmead worked in the Pharmaceutical industry for over thirty years, holding executive leadership roles with ICI. These included leading the commercialisation of a range of cancer medicines, management of the ICI Pharma businesses in Asia and as President and Chair of AstraZeneca UK. He was President of the ABPI from 2008 to 2010. Since 2010 he has been a non executive director on several boards including UDG plc, Domino Printing Sciences plc and the Wesleyan Assurance Society. He chairs two private companies, Proveca Ltd and Bamburgh Capital Ltd and recently joined the board of Cambian group plc. Chris is a Member of Council at Imperial College and an advisor and champion on Life Sciences for the UK Government. He was appointed a CBE in January 2015.
Helen Shaw - Co Managing Director
Helen Shaw is a qualified doctor with over 20 years' experience as a medical professional in the pharmaceutical industry. She has a proven track record in providing strategic direction and focus in product development and innovation and her experience covers all drug and device classifications, and all stages of development and marketing, in a global arena. Helen’s expertise is in providing leadership and strategic direction at Board level, fostering excellent relationships with key stakeholders and regulatory authorities and translating technical and regulatory needs into clear development programmes to maximise shareholder value.
Helen is a non-executive board member of Mode Health and has been a non-executive board member with Zilico Ltd, Syntopix Group plc. and Auralis Ltd. She is Chairman of Four Shaw Consulting Ltd and co-managing director of Proveca. As Medical Director of Boots Healthcare International Helen had a strong track record in international product development, prescription to over-the-counter switching, in-licensing and joint ventures for brands such as Clearasil, Nurofen, Strepsils and Optrex. As non-executive Medical Director to Auralis Ltd, Helen provided key strategic and hands-on input to the development portfolio and product licensing, including gaining the PUMA for Buccolam.
Simon Bryson - Co Managing Director
Simon has 24 years’ experience within the pharmaceutical and biopharmaceutical industry. During this time he has held a number of senior management positions with GlaxoSmithKline, PowderJect and Chiron Vaccines across research and development and commercial operations. Simon’s expertise is in providing leadership and expertise on new product identification, development and licensing. As co-founder and joint managing Director of Auralis Ltd, Simon led the company through to a x5.4 fold return on investment when the company was acquired in May 2010 for £20m. Simon has a BSc (Hons) degree in Biochemistry, a Masters degree in Industrial Pharmaceutical Studies and a PhD in Paediatric medication adherence.
Simon Barter - Commercial Director
Simon is an experienced pharmaceutical professional having held several significant senior level roles including the head of Global Marketing capability for AstraZeneca, the head of the Global Commercial Innovation function.
He has a track record of delivery in global marketing, innovation, corporate and portfolio strategy and operating company delivery. He has broad therapeutic experience having led the commercial therapy areas for Pain, Anaesthesia, Infection and Oncology.
Simon has lived and worked across several European countries in sales and marketing roles, amassing first hand experience of several healthcare systems. Simon has a BSc (Hons) from London University and a Masters in Science of Management from Boston University.
Andrew Jackson - Financial Director
Andrew Jackson is Financial Director of Proveca and a Partner at summ.it, a commercially focused accountancy and IT business.
Having qualified in 2000 Andrew joined summ.it in 2001 and has now been with the firm for over 10 years. Andrew acts for a wide portfolio of clients and has extensive experience of working with limited companies and dealing with entrepreneurial, privately owned and VC backed SME’s. Throughout his time with summ.it Andrew has worked closely with his clients to understand each company’s strategic objectives and the overall aims of the business and its owners
Christoph Ruedig - Investor Director
Christoph joined Albion Ventures as an Investment Manager in October 2011 and focuses on investments in healthcare and renewables. He initially practised as a radiologist, before spending 3 years at Bain & Company. In 2006, he joined 3i working for their Healthcare Venture Capital arm. Most recently he has worked for General Electric's healthcare division, where he was responsible for mergers and acquisitions in the medical technology and healthcare IT sectors. He holds a degree in medicine from Ludwig-Maximilians University, Munich and an MBA from INSEAD.
Gareth King - Investor Director
Gareth is a Life Science Partner with Catapult’s GM&C Life Sciences Fund, an investor in Proveca. Gareth was most recently CEO of Critical Pharmaceuticals, a clinical stage biotechnology company utilising a proprietary drug delivery technology to develop a pipeline of unique biological drug products, whose investors included Catapult Ventures and the Welcome Trust. Gareth was previously VP Business Development at Pharmaceutical Profiles, which he joined from Manchester-based start-up Cyprotex, where he was Commercial Director. Gareth began his career in Boston, USA as a Research Fellow at Harvard Medical School. He moved back to the UK and was based at Alderley Park for over 3 years as Bioinformatics Project Manager with AstraZeneca, before joining California-based genomics company Incyte. Gareth holds an BSc in Microbiology from Sheffield University and a PhD in Molecular Genetics from Edinburgh University.